MedDataX Logo

Insulin Resistance and Substrate Metabolism After Acute Erythropoietin (EPO) Administration

NCT ID: NCT00793767

Last Updated: 2009-05-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Recently EPO receptors have been found in human muscle tissue, but what is still not known is the physiological role of these receptors. In this study the researchers want to investigate if there is any effect of a acute administration of EPO on insulin resistance and/or substrate metabolism in muscle tissue.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Recently EPO receptors have been found in human muscle tissue, but what is still not known is what the physiological role of these receptors are. It has previously been shown that Growth Hormone mediate insulin resistance. The GH receptor and EPO receptor belong to the same family of cytokine receptors, and thereby share many of the same signalling pathways. In this study we want to investigate if there is a similar effect on insulin resistance and/or substrate metabolism after acute administration of EPO in human muscle tissue. Different signalling pathways are investigated på western blotting, and insulin sensitivity are measured be a hyperinsulinemic euglycemic clamp, and substrate metabolism is measured by the forearm model.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Insulin Sensitivity

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Erythropoietin human muscle tissue insulin sensitivity substrate metabolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

placebo

placebo

Group Type PLACEBO_COMPARATOR

placebo (saline)

Intervention Type DRUG

i.v

Erythropoietin

acute administration of erythropoietin

Group Type EXPERIMENTAL

erythropoietin

Intervention Type DRUG

bolus of 400 IU/kg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

erythropoietin

bolus of 400 IU/kg

Intervention Type DRUG

placebo (saline)

i.v

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy persons
* Between 18 and 30 years
* Normal weight (BMI: 18-25)

Exclusion Criteria

* Severe heart disease (NYHA 3)
* Uncontrolled hypertension
* Previous cerebrovascular disease
* Proliferative retinopathy
* Diabetes
* Musculo-skeletal diseases
Minimum Eligible Age

18 Years

Maximum Eligible Age

30 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aarhus University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Afdeling M, Århus sygehus

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medicinsk forsknings laboratorium

Århus C, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

M-20080016

Identifier Type: -

Identifier Source: org_study_id